Injected Xolair Therapy Could Prevent Food Allergies in Kids
By Dennis Thompson HealthDay Reporter
THURSDAY, Dec. 21, 2023 -- A new treatment appears to reduce food allergies in children and teens, according to interim clinical trial results.
A lab-made monoclonal antibody called omalizumab (Xolair) significantly increased the amounts of common foods that children could eat without sparking an allergic reaction, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) reported.
The U.S. Food and Drug Administration is now reviewing an application for omalizumab to treat food allergies, based on these interim results.
The data was collected on 165 children ages 17 and younger who have an allergy to peanut and at least two other foods, NIAID said in a news release.
Those who received omalizumab injections could consume more peanut, egg, milk and cashew products without allergic reactions than those who received a placebo jab, results showed.
Kids receive the drug in biweekly or monthly injections, according to an NIAID description of the clinical trial.
These first-stage results have given NIAID the confidence to launch the next stage of clinical trials, which will be conducted at 10 locations across the United States.
Omalizumab has already been approved by the U.S. Food and Drug Administration to treat allergic asthma, chronic hives and nasal polyps, according to the Cleveland Clinic.
In 2017, a small study of 48 people found that 83% of participants could consume 2 grams of two food allergens after receiving omalizumab injections, compared to only 33% of people in a placebo group.
Xolair is developed and marketed by the drug companies Genentech and Norvartis Pharmaceuticals, NIAID said. The companies are supplying the medication for the trial, which was funded by NIAID.
Sources
- National Institute of Allergy and Infectious Diseases, news release, Dec. 19, 2023
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
FDA Warns Top National Bakery to Stop Listing Allergens in Products When They Aren't There
FRIDAY, June 28, 2024 -- The U.S. Food and Drug Administration has sent a warning letter to one of America's biggest bakeries, asking the company to stop claiming there are...
Anti- Seizure Meds Are Crucial, But Can Trigger Severe Reactions
MONDAY, June 24, 2024 -- Specific steps can be taken to reduce the risk of potentially fatal reactions to anti-seizure medications, researchers report in a new review. Performing...
Early Exposure to Peanuts Can Prevent Long-Term Allergy
WEDNESDAY, May 29, 2024 -- Feeding kids peanuts early in childhood can drastically reduce their risk of developing a peanut allergy, a new clinical trial reports. Children...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.